×
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
NASDAQ:TNXP

Tonix Pharmaceuticals Stock Forecast, Price & News

$1.58
-0.08 (-4.82%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.53
$1.62
50-Day Range
$1.66
$70.72
52-Week Range
$1.53
$36.48
Volume
2.29 million shs
Average Volume
3.47 million shs
Market Capitalization
$26.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.60
30 days | 90 days | 365 days | Advanced Chart

Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Stock Forecast (MarketRank)

Overall MarketRank

1.76 out of 5 stars

Medical Sector

851st out of 1,433 stocks

Pharmaceutical Preparations Industry

420th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Tonix Pharmaceuticals logo

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

TNXP Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNXP
Employees
73
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
6/30/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$41.60
High Stock Price Forecast
$64.00
Low Stock Price Forecast
$19.20
Forecasted Upside/Downside
+2,532.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-92.29 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.08 per share

Miscellaneous

Free Float
16,378,000
Market Cap
$26.40 million
Optionable
Optionable
Beta
1.44














Tonix Pharmaceuticals Frequently Asked Questions

Should I buy or sell Tonix Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tonix Pharmaceuticals stock.
View analyst ratings for Tonix Pharmaceuticals
or view top-rated stocks.

What is Tonix Pharmaceuticals' stock price forecast for 2022?

2 equities research analysts have issued 12 month price targets for Tonix Pharmaceuticals' stock. Their TNXP stock forecasts range from $19.20 to $64.00. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $41.60 in the next year. This suggests a possible upside of 2,532.9% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Tonix Pharmaceuticals' stock performed in 2022?

Tonix Pharmaceuticals' stock was trading at $11.4464 at the beginning of the year. Since then, TNXP stock has decreased by 86.2% and is now trading at $1.58.
View the best growth stocks for 2022 here
.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Tonix Pharmaceuticals
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its earnings results on Monday, May, 9th. The company reported ($1.60) EPS for the quarter, meeting analysts' consensus estimates of ($1.60).
View Tonix Pharmaceuticals' earnings history
.

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Shares of Tonix Pharmaceuticals reverse split before market open on Tuesday, May 17th 2022. The 1-32 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 17th 2022. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the following people:
  • Dr. Seth Lederman M.D., Co-Founder, Pres, CEO & Chairman (Age 64, Pay $1.18M) (LinkedIn Profile)
  • Mr. Bradley Saenger CPA, CPA, CFO & Treasurer (Age 48, Pay $595k)
  • Dr. Gregory M. Sullivan M.D., Chief Medical Officer & Sec. (Age 56, Pay $616k)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Herbert W. Harris M.D., Ph.D., Exec. VP of Translational Medicine
  • Dr. Bruce L. Daugherty M.B.A., Ph.D., Exec. VP of Research (Age 64)
  • Ms. Siobhan Fogarty B.Sc., M.Sc., Exec. VP of Product Devel.
  • Dr. Darryl Rideout Ph.D., Exec. VP of Experimental Chemistry
  • Dr. Anthony Macaluso Ph.D., Exec. VP of Strategic Devel.
  • Dr. Daniel J. Clauw M.D., Consultant

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $1.58.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals (NASDAQ:TNXP) has a market capitalization of $26.40 million. The company earns $-92.29 million in net income (profit) each year or ($7.667740) on an earnings per share basis.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals employs 73 workers across the globe.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The official website for Tonix Pharmaceuticals is www.tonixpharma.com. The company can be reached via phone at (212) 980-9155, via email at [email protected], or via fax at 212-923-5700.

This page (NASDAQ:TNXP) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.